<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587727</url>
  </required_header>
  <id_info>
    <org_study_id>18-0479</org_study_id>
    <nct_id>NCT03587727</nct_id>
  </id_info>
  <brief_title>Hepatic Mitochondrial Function in Youth</brief_title>
  <acronym>MANGO</acronym>
  <official_title>Hepatic Fat Content and Mitochondrial Flux in Obese Youth Before and After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the impact of bariatric surgery on hepatic energy metabolism and glucose and insulin
      dynamics in obese youth
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A metabolic study that will be performed prior to and 12 months following bariatric surgery.
      The study will include 31-phosphorus magnetic resonance spectroscopy to measure phosphate
      concentrations in the liver; a 4 hour mixed meal tolerance test, an intravenous arginine
      test, Abdominal Magnetic Resonance Imaging (MRI) for visceral and hepatic fat, Magnetic
      Resonance (MR) Elastography of the liver, indirect calorimetry, body composition assessment
      with Bodpod, serum metabolomics and hepatic tissue mitochondrial measures from the time of
      surgery only.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Hepatic mitochondrial function</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Hepatic mitochondrial function will be measured with 31 phosphorus MR Spectroscopy: Hepatic mitochondrial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Hepatic mitochondrial function</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Hepatic mitochondrial function will be measured with 31 phosphorus MR Spectroscopy Magnetic Resonance Imaging: MRE, hepatic fat fraction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Resistance/pancreas/GI hormones</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Mixed meal tolerance test (MMT): Insulin sensitivity to determine maximal insulin secretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Resistance/pancreas/GI hormones</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Mixed meal tolerance test (MMT): Hyperglycemia to determine maximal insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Resistance/pancreas/GI hormones</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Mixed meal tolerance test (MMT): Hypoglycemia to determine maximal insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Resistance/pancreas/GI hormones</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Mixed meal tolerance test (MMT): Insulin/C-peptide response to determine maximal insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Resistance/pancreas/GI hormones</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Mixed meal tolerance test (MMT): GLP-1 to determine maximal insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Resistance/pancreas/GI hormones</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Mixed meal tolerance test (MMT): Glucagon response to determine maximal insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NAFLD via MRI</measure>
    <time_frame>Prior to bariatric surgery and 1 year post-bariatric surgery</time_frame>
    <description>Changes, if any, will be documented through the use of Magnetic Resonance (MR) elastography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Tissue hepatic mitochondrial function</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Glucose will be assessed with Oroboros</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Tissue hepatic mitochondrial function</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Fat oxidation will be assessed with Oroboros</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NAFLD status via tissue</measure>
    <time_frame>At time of surgery</time_frame>
    <description>NAFLD status will be determined by biopsy at the time of surgery</description>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hepatic Steatosis</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Adolescent Obesity</condition>
  <condition>Obesity</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      With participant consent, samples will be kept and may be used in future research to learn
      more about NAFLD and risk for type 2 diabetes.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals age 13-20 years; Body Mass Index 35-55 m2/kg; Scheduled for Bariatric Surgery
        at Children's Hospital Colorado.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Obese youth ages 13-20 years, scheduled for bariatric surgery at Children's Hospital
             Colorado

          2. BMI 35-55 m2/kg

          3. Maximal body circumference &lt;200 cm

        Exclusion Criteria:

          1. Use of medications known to affect insulin sensitivity: oral glucocorticoids within
             10; days, atypical antipsychotics, immunosuppressant agents, HIV medications.

          2. Infectious hepatitis

          3. Alcohol abuse

          4. Mitochondrial disease

          5. Type 2 diabetes

          6. Medications that affect hepatic outcomes (e.g. PPAR-γ or PPAR-α, metformin)

          7. Currently pregnant or breastfeeding women. Development of pregnancy during the study
             period will necessitate withdrawal from the study.

          8. Severe illness requiring hospitalization within 60 days

          9. Diabetes, defined as Hemoglobin A1C &gt; 6.4%

         10. Anemia, defined as Hemoglobin &lt; 10 mg/dL

         11. Diagnosed major psychiatric or developmental disorder limiting informed consent

         12. Implanted metal devices that are not compatible with MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Cree-Green, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Cree-Green, MD, PhD</last_name>
    <phone>720 777-6128</phone>
    <email>melanie.green@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yesenia Garcia-Reyes, MS</last_name>
    <phone>720 777-6984</phone>
    <email>yesenia.garciareyes@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Anshutz Medical Campus/Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesenia Garcia Reyes</last_name>
      <phone>720-777-6984</phone>
      <email>yesenia.garciareyes@childrenscolorado.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bariatric surgery</keyword>
  <keyword>hepatic mitochondria</keyword>
  <keyword>insulin secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

